Ixazomib ( DrugBank: Ixazomib )

4 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	1
16	Crow-Fukase syndrome	1
28	Systemic amyloidosis	4
51	Scleroderma	1

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03783416 (ClinicalTrials.gov)	June 1, 2019	10/12/2018	SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis	Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis: A Phase 1b Randomised, Double-blind, Placebo-controlled Trial.	Relapsing Remitting Multiple Sclerosis;Primary Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis	Drug: Ixazomib (NINLARO®) capsules / Matching placebo capsules	Queen Mary University of London	Takeda Pharmaceuticals International, Inc.	Not yet recruiting	18 Years	65 Years	All	72	Phase 1	United Kingdom

16. Crow-Fukase syndrome

Clinical trials : 13 / Drugs : 14 - (DrugBank : 7) / Drug target genes : 4 - Drug target pathways : 75

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02921893 (ClinicalTrials.gov)	October 31, 2016	26/9/2016	Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome	Ixazomib, Lenalidomide, and Dexamethasone for Patients With POEMS Syndrome	Plasmacytoma;POEMS Syndrome	Drug: Dexamethasone;Drug: Ixazomib Citrate;Drug: Lenalidomide;Other: Questionnaire Administration	Mayo Clinic	National Cancer Institute (NCI)	Active, not recruiting	18 Years	N/A	All	21	Early Phase 1	United States

28. Systemic amyloidosis

Clinical trials : 267 / Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05451771 (ClinicalTrials.gov)	October 26, 2022	6/7/2022	Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis	An Open-label Phase I/II Trial of Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Systemic Light-Chain Amyloidosis	AL Amyloidosis	Drug: Venetoclax Oral Tablet, 200 mg;Device: FISH assay;Drug: Venetoclax Oral Tablet, 400 mg;Drug: Dexamethasone Oral, 10 mg;Drug: Dexamethasone Oral, 20 mg;Drug: Daratumumab Injection;Drug: Bendamustine;Drug: Pomalidomide;Drug: Ixazomib;Drug: Venetoclax MTD with Dexamethasone	Rajshekhar Chakraborty, MD	Genentech, Inc.	Recruiting	18 Years	N/A	All	53	Phase 1/Phase 2	United States
2	NCT03618537 (ClinicalTrials.gov)	August 2, 2018	2/8/2018	Ixazomib Maintenance Study in Patients With AL Amyloidosis	Ixazomib Maintenance Following Initial Therapy in Patients With Immunoglobulin Light Chain (AL) Amyloidosis	AL Amyloidosis	Drug: Ixazomib;Drug: Dexamethasone	Memorial Sloan Kettering Cancer Center	Tufts Medical Center;Vanderbilt University Medical Center	Recruiting	18 Years	N/A	All	47	Phase 2	United States
3	NCT03283917 (ClinicalTrials.gov)	February 7, 2018	13/9/2017	Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis	A Safety Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis	Newly Diagnosed Primary Amyloidosis;Recurrent Primary Amyloidosis;Refractory Primary Amyloidosis	Biological: Daratumumab;Drug: Dexamethasone;Drug: Ixazomib	M.D. Anderson Cancer Center	Janssen Pharmaceuticals;Takeda	Recruiting	18 Years	N/A	All	20	Phase 1	United States
4	NCT03236792 (ClinicalTrials.gov)	June 12, 2017	20/7/2017	Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis	Phase 1/2 Study Of Ixazomib In Combination With Cyclophosphamide And Dexamethasone In Patients With Newly Diagnosed Immunoglobulin Light Chain AL Amyloidosis	AL Amyloidosis	Drug: Ixazomib;Drug: Cyclophosphamide;Drug: Dexamethasone	Icahn School of Medicine at Mount Sinai	Millennium Pharmaceuticals, Inc.	Completed	18 Years	N/A	All	28	Phase 1/Phase 2	United States

51. Scleroderma

Clinical trials : 525 / Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04837131 (ClinicalTrials.gov)	April 28, 2021	5/4/2021	A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients	A Phase 2 Open-Label Pilot Study of the Safety and Tolerability of Ixazomib Administered Orally to Patients With Scleroderma-Related Interstitial Lung Disease	Systemic Sclerosis;Scleroderma;Diffuse Systemic Sclerosis;Diffuse Scleroderma;Diffuse Cutaneous Systemic Sclerosis;Diffuse Cutaneous Scleroderma;Progressive Systemic Sclerosis;Progressive Scleroderma;Scleroderma, Systemic;Scleroderma, Diffuse;Progressive;Systemic Sclerosis, Diffuse;Systemic; Sclerosis, Progressive;Scleroderma of Lung;Scleroderma With Pulmonary Involvement;Systemic Sclerosis Pulmonary;Systemic Sclerosis With Lung Involvement;Interstitial Lung Disease;Pulmonary Fibrosis Interstitial	Drug: Ixazomib	W. Leroy Griffing	NULL	Recruiting	18 Years	N/A	All	12	Phase 2	United States